Lord, Abbett & Co
CTKB icon

Lord, Abbett & Co’s Cytek Biosciences CTKB Stock Holding History

Lord, Abbett & Co’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-498,448
Closed -$4.58M – 544
2023
Q1 		$4.58M Buy
498,448
+21,282
+4% +$229K 0.02% 483
2022
Q4 		$4.87M Buy
+477,166
New +$6.41M 0.02% 504

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Lord, Abbett & Co's CTKB Position: Q2 2023 in Review

Lord, Abbett & Co sold out of Cytek Biosciences (CTKB) in Q2 2023, closing a stake of 498,448 shares — an estimated $4.58M sold.

Lord, Abbett & Co first reported a position in CTKB in Q4 2022 and held it in 2 quarters. The position peaked at $4.87M in Q4 2022. 101 funds tracked by Wall St. Rank hold CTKB as of Q2 2023.

  • Lord, Abbett & Co reported no remaining Cytek Biosciences position as of Q2 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 498,448 Cytek Biosciences shares in Q2 2023, an estimated $4.58M.
  • Lord, Abbett & Co first reported a position in Cytek Biosciences in Q4 2022 and held it in 2 quarters.
  • Lord, Abbett & Co's Cytek Biosciences position peaked at $4.87M in Q4 2022.
  • 101 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2023.

Based on Lord, Abbett & Co's 13F filing for Q2 2023, filed 14 Aug 2023.